Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ligand Beginning New Cancer Trial

By Drug Discovery Trends Editor | June 23, 2011

SAN DIEGO (AP) – Ligand Pharmaceuticals Inc. said it will start a new trial of a potential cancer drug, and if studies are successful, it will seek marketing approval in mid-2013.

Ligand said it plans to start a pivotal trial in early 2012, enrolling about 60 patients with multiple myeloma, a cancer that affects plasma cells in bone marrow. It plans to file with the Food and Drug Administration by mid-2013 if the study is successful. The company is planning to report full results from a mid-stage study during the fourth quarter.

The company is studying a version of the drug melphalan, which is already used to treat multiple myeloma. Ligand said its version of the drug excludes an ingredient that is reported to cause kidney and heart side effects. Those side effects force physicians to use smaller doses of the drug, and Ligand said its version would make it possible to treat patients longer, use slower infusions, and possibly use higher doses safely.

Ligand’s drug candidate has received orphan drug status from the FDA, meaning the company will have up to seven years of marketing exclusivity if it is approved. Orphan drug status is given to treatments for rare diseases and to diseases that have few available treatments.

Date: June 22, 2011
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50